ParkinsonFranceV1, PascalFrancis, Corpus, bibRecord, 001933

Chronic MPTP treatment reproduces in baboons the differential vulnerability of mesencephalic dopaminergic neurons observed in Parkinson's disease

Identifieur interne : 001933 ( PascalFrancis/Corpus ); précédent : 001932; suivant : 001934

Chronic MPTP treatment reproduces in baboons the differential vulnerability of mesencephalic dopaminergic neurons observed in Parkinson's disease

Auteurs : M. Varastet ; D. Riche ; M. Maziere ; P. Hantraye

Source :

Neuroscience [ 0306-4522 ] ; 1994.

RBID : Pascal:94-0715673

Descripteurs français

Pascal (Inist)
- Tyrosine 3-monooxygenase, Mésencéphale, Neurone dopaminergique, Parkinson maladie, Neurotoxine, Pathologie expérimentale, Animal, Singe, MPTP.

English descriptors

KwdEn :
- Animal, Dopaminergic neuron, Experimental disease, Midbrain, Monkey, Neurotoxin, Parkinson disease, Tyrosine 3-monooxygenase.

Abstract

Chronic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to baboons was shown previously to result in a motor syndrome and a pattern of striatal dopaminergic fibre loss similar to those observed in idiopathic Parkinson's disease. In the present study, tyrosine hydroxylase-immunoreactive neurons were qwantified in the mesencephalon of control (n=4) and chronically MPTP-treated (n=3) baboons. MPTP induced a significant reduction in neuronal cell density in the substantia nigra (63.8% reduction) and the ventral tegmental area (53.1%). Within the substantia nigra, obvious mediolateral and dorsoventral gradients of neuronal cell loss were observed

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0306-4522`
A02	`01`			`@0 NRSCDN`
A03		`1`		`@0 Neuroscience`
A05				`@2 63`
A06				`@2 1`
A08	`01`	`1`	`ENG`	`@1 Chronic MPTP treatment reproduces in baboons the differential vulnerability of mesencephalic dopaminergic neurons observed in Parkinson's disease`
A11	`01`	`1`		`@1 VARASTET (M.)`
A11	`02`	`1`		`@1 RICHE (D.)`
A11	`03`	`1`		`@1 MAZIERE (M.)`
A11	`04`	`1`		`@1 HANTRAYE (P.)`
A14	`01`			`@1 CEA CNRS, DRIPP, serv. hosp. Frédéric Joliot @2 91401 Orsay @3 FRA @Z 1 aut. @Z 3 aut. @Z 4 aut.`
A14	`02`			`@1 CNRS Inst. Alfred Fessard @2 91198 Gif-sur-Yvette @3 FRA @Z 2 aut.`
A20				`@1 47-56`
A21				`@1 1994`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 17194 @5 354000042107130050`
A44				`@0 0000`
A45				`@0 61 ref.`
A47	`01`	`1`		`@0 94-0715673`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Neuroscience`
A66	`01`			`@0 GBR`
C01	`01`		`ENG`	@0 Chronic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to baboons was shown previously to result in a motor syndrome and a pattern of striatal dopaminergic fibre loss similar to those observed in idiopathic Parkinson's disease. In the present study, tyrosine hydroxylase-immunoreactive neurons were qwantified in the mesencephalon of control (n=4) and chronically MPTP-treated (n=3) baboons. MPTP induced a significant reduction in neuronal cell density in the substantia nigra (63.8% reduction) and the ventral tegmental area (53.1%). Within the substantia nigra, obvious mediolateral and dorsoventral gradients of neuronal cell loss were observed
C02	`01`	`X`		`@0 002B17G`
C03	`01`	`X`	`FRE`	`@0 Tyrosine 3-monooxygenase @2 FE @5 01 @6 Tyrosine «3»-monooxygenase`
C03	`01`	`X`	`ENG`	`@0 Tyrosine 3-monooxygenase @2 FE @5 01 @6 Tyrosine «3»-monooxygenase`
C03	`01`	`X`	`SPA`	`@0 Tyrosine 3-monooxygenase @2 FE @5 01 @6 Tyrosine «3»-monooxygenase`
C03	`02`	`X`	`FRE`	`@0 Mésencéphale @5 02`
C03	`02`	`X`	`ENG`	`@0 Midbrain @5 02`
C03	`02`	`X`	`SPA`	`@0 Mesencéfalo @5 02`
C03	`03`	`X`	`FRE`	`@0 Neurone dopaminergique @5 03`
C03	`03`	`X`	`ENG`	`@0 Dopaminergic neuron @5 03`
C03	`03`	`X`	`SPA`	`@0 Neurona dopaminérgica @5 03`
C03	`04`	`X`	`FRE`	`@0 Parkinson maladie @2 NM @5 04`
C03	`04`	`X`	`ENG`	`@0 Parkinson disease @2 NM @5 04`
C03	`04`	`X`	`SPA`	`@0 Parkinson enfermedad @2 NM @5 04`
C03	`05`	`X`	`FRE`	`@0 Neurotoxine @5 12`
C03	`05`	`X`	`ENG`	`@0 Neurotoxin @5 12`
C03	`05`	`X`	`SPA`	`@0 Neurotoxina @5 12`
C03	`06`	`X`	`FRE`	`@0 Pathologie expérimentale @5 13`
C03	`06`	`X`	`ENG`	`@0 Experimental disease @5 13`
C03	`06`	`X`	`SPA`	`@0 Patología experimental @5 13`
C03	`07`	`X`	`FRE`	`@0 Animal @5 14`
C03	`07`	`X`	`ENG`	`@0 Animal @5 14`
C03	`07`	`X`	`SPA`	`@0 Animal @5 14`
C03	`08`	`X`	`FRE`	`@0 Singe @5 41`
C03	`08`	`X`	`ENG`	`@0 Monkey @5 41`
C03	`08`	`X`	`SPA`	`@0 Mono @5 41`
C03	`09`	`X`	`FRE`	`@0 MPTP @4 INC @5 89`
C07	`01`	`X`	`FRE`	`@0 Oxidoreductases @2 FE`
C07	`01`	`X`	`ENG`	`@0 Oxidoreductases @2 FE`
C07	`01`	`X`	`SPA`	`@0 Oxidoreductases @2 FE`
C07	`02`	`X`	`FRE`	`@0 Enzyme`
C07	`02`	`X`	`ENG`	`@0 Enzyme`
C07	`02`	`X`	`SPA`	`@0 Enzima`
C07	`03`	`X`	`FRE`	`@0 Système nerveux central @5 20`
C07	`03`	`X`	`ENG`	`@0 Central nervous system @5 20`
C07	`03`	`X`	`SPA`	`@0 Sistema nervioso central @5 20`
C07	`04`	`X`	`FRE`	`@0 Maladie dégénérative @5 26`
C07	`04`	`X`	`ENG`	`@0 Degenerative disease @5 26`
C07	`04`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 26`
C07	`05`	`X`	`FRE`	`@0 Système nerveux pathologie @5 27`
C07	`05`	`X`	`ENG`	`@0 Nervous system diseases @5 27`
C07	`05`	`X`	`SPA`	`@0 Sistema nervioso patología @5 27`
C07	`06`	`X`	`FRE`	`@0 Primates @2 NS`
C07	`06`	`X`	`ENG`	`@0 Primates @2 NS`
C07	`06`	`X`	`SPA`	`@0 Primates @2 NS`
C07	`07`	`X`	`FRE`	`@0 Mammalia @2 NS`
C07	`07`	`X`	`ENG`	`@0 Mammalia @2 NS`
C07	`07`	`X`	`SPA`	`@0 Mammalia @2 NS`
C07	`08`	`X`	`FRE`	`@0 Vertebrata @2 NS`
C07	`08`	`X`	`ENG`	`@0 Vertebrata @2 NS`
C07	`08`	`X`	`SPA`	`@0 Vertebrata @2 NS`
N21				`@1 353`

Format Inist (serveur)

NO :	PASCAL 94-0715673 INIST
ET :	Chronic MPTP treatment reproduces in baboons the differential vulnerability of mesencephalic dopaminergic neurons observed in Parkinson's disease
AU :	VARASTET (M.); RICHE (D.); MAZIERE (M.); HANTRAYE (P.)
AF :	CEA CNRS, DRIPP, serv. hosp. Frédéric Joliot/91401 Orsay/France (1 aut., 3 aut., 4 aut.); CNRS Inst. Alfred Fessard/91198 Gif-sur-Yvette/France (2 aut.)
DT :	Publication en série; Niveau analytique
SO :	Neuroscience; ISSN 0306-4522; Coden NRSCDN; Royaume-Uni; Da. 1994; Vol. 63; No. 1; Pp. 47-56; Bibl. 61 ref.
LA :	Anglais
EA :	Chronic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to baboons was shown previously to result in a motor syndrome and a pattern of striatal dopaminergic fibre loss similar to those observed in idiopathic Parkinson's disease. In the present study, tyrosine hydroxylase-immunoreactive neurons were qwantified in the mesencephalon of control (n=4) and chronically MPTP-treated (n=3) baboons. MPTP induced a significant reduction in neuronal cell density in the substantia nigra (63.8% reduction) and the ventral tegmental area (53.1%). Within the substantia nigra, obvious mediolateral and dorsoventral gradients of neuronal cell loss were observed
CC :	002B17G
FD :	Tyrosine 3-monooxygenase; Mésencéphale; Neurone dopaminergique; Parkinson maladie; Neurotoxine; Pathologie expérimentale; Animal; Singe; MPTP
FG :	Oxidoreductases; Enzyme; Système nerveux central; Maladie dégénérative; Système nerveux pathologie; Primates; Mammalia; Vertebrata
ED :	Tyrosine 3-monooxygenase; Midbrain; Dopaminergic neuron; Parkinson disease; Neurotoxin; Experimental disease; Animal; Monkey
EG :	Oxidoreductases; Enzyme; Central nervous system; Degenerative disease; Nervous system diseases; Primates; Mammalia; Vertebrata
SD :	Tyrosine 3-monooxygenase; Mesencéfalo; Neurona dopaminérgica; Parkinson enfermedad; Neurotoxina; Patología experimental; Animal; Mono
LO :	INIST-17194.354000042107130050
ID :	94-0715673

Links to Exploration step

Pascal:94-0715673

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Chronic MPTP treatment reproduces in baboons the differential vulnerability of mesencephalic dopaminergic neurons observed in Parkinson's disease</title>
<author><name sortKey="Varastet, M" sort="Varastet, M" uniqKey="Varastet M" first="M." last="Varastet">M. Varastet</name>
<affiliation><inist:fA14 i1="01"><s1>CEA CNRS, DRIPP, serv. hosp. Frédéric Joliot</s1>
<s2>91401 Orsay</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Riche, D" sort="Riche, D" uniqKey="Riche D" first="D." last="Riche">D. Riche</name>
<affiliation><inist:fA14 i1="02"><s1>CNRS Inst. Alfred Fessard</s1>
<s2>91198 Gif-sur-Yvette</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Maziere, M" sort="Maziere, M" uniqKey="Maziere M" first="M." last="Maziere">M. Maziere</name>
<affiliation><inist:fA14 i1="01"><s1>CEA CNRS, DRIPP, serv. hosp. Frédéric Joliot</s1>
<s2>91401 Orsay</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hantraye, P" sort="Hantraye, P" uniqKey="Hantraye P" first="P." last="Hantraye">P. Hantraye</name>
<affiliation><inist:fA14 i1="01"><s1>CEA CNRS, DRIPP, serv. hosp. Frédéric Joliot</s1>
<s2>91401 Orsay</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">94-0715673</idno>
<date when="1994">1994</date>
<idno type="stanalyst">PASCAL 94-0715673 INIST</idno>
<idno type="RBID">Pascal:94-0715673</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001933</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Chronic MPTP treatment reproduces in baboons the differential vulnerability of mesencephalic dopaminergic neurons observed in Parkinson's disease</title>
<author><name sortKey="Varastet, M" sort="Varastet, M" uniqKey="Varastet M" first="M." last="Varastet">M. Varastet</name>
<affiliation><inist:fA14 i1="01"><s1>CEA CNRS, DRIPP, serv. hosp. Frédéric Joliot</s1>
<s2>91401 Orsay</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Riche, D" sort="Riche, D" uniqKey="Riche D" first="D." last="Riche">D. Riche</name>
<affiliation><inist:fA14 i1="02"><s1>CNRS Inst. Alfred Fessard</s1>
<s2>91198 Gif-sur-Yvette</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Maziere, M" sort="Maziere, M" uniqKey="Maziere M" first="M." last="Maziere">M. Maziere</name>
<affiliation><inist:fA14 i1="01"><s1>CEA CNRS, DRIPP, serv. hosp. Frédéric Joliot</s1>
<s2>91401 Orsay</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hantraye, P" sort="Hantraye, P" uniqKey="Hantraye P" first="P." last="Hantraye">P. Hantraye</name>
<affiliation><inist:fA14 i1="01"><s1>CEA CNRS, DRIPP, serv. hosp. Frédéric Joliot</s1>
<s2>91401 Orsay</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Neuroscience</title>
<title level="j" type="abbreviated">Neuroscience</title>
<idno type="ISSN">0306-4522</idno>
<imprint><date when="1994">1994</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Neuroscience</title>
<title level="j" type="abbreviated">Neuroscience</title>
<idno type="ISSN">0306-4522</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animal</term>
<term>Dopaminergic neuron</term>
<term>Experimental disease</term>
<term>Midbrain</term>
<term>Monkey</term>
<term>Neurotoxin</term>
<term>Parkinson disease</term>
<term>Tyrosine 3-monooxygenase</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Tyrosine 3-monooxygenase</term>
<term>Mésencéphale</term>
<term>Neurone dopaminergique</term>
<term>Parkinson maladie</term>
<term>Neurotoxine</term>
<term>Pathologie expérimentale</term>
<term>Animal</term>
<term>Singe</term>
<term>MPTP</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Chronic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to baboons was shown previously to result in a motor syndrome and a pattern of striatal dopaminergic fibre loss similar to those observed in idiopathic Parkinson's disease. In the present study, tyrosine hydroxylase-immunoreactive neurons were qwantified in the mesencephalon of control (n=4) and chronically MPTP-treated (n=3) baboons. MPTP induced a significant reduction in neuronal cell density in the substantia nigra (63.8% reduction) and the ventral tegmental area (53.1%). Within the substantia nigra, obvious mediolateral and dorsoventral gradients of neuronal cell loss were observed</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0306-4522</s0>
</fA01>
<fA02 i1="01"><s0>NRSCDN</s0>
</fA02>
<fA03 i2="1"><s0>Neuroscience</s0>
</fA03>
<fA05><s2>63</s2>
</fA05>
<fA06><s2>1</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Chronic MPTP treatment reproduces in baboons the differential vulnerability of mesencephalic dopaminergic neurons observed in Parkinson's disease</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>VARASTET (M.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>RICHE (D.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>MAZIERE (M.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>HANTRAYE (P.)</s1>
</fA11>
<fA14 i1="01"><s1>CEA CNRS, DRIPP, serv. hosp. Frédéric Joliot</s1>
<s2>91401 Orsay</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>CNRS Inst. Alfred Fessard</s1>
<s2>91198 Gif-sur-Yvette</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA20><s1>47-56</s1>
</fA20>
<fA21><s1>1994</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>17194</s2>
<s5>354000042107130050</s5>
</fA43>
<fA44><s0>0000</s0>
</fA44>
<fA45><s0>61 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>94-0715673</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Neuroscience</s0>
</fA64>
<fA66 i1="01"><s0>GBR</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Chronic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to baboons was shown previously to result in a motor syndrome and a pattern of striatal dopaminergic fibre loss similar to those observed in idiopathic Parkinson's disease. In the present study, tyrosine hydroxylase-immunoreactive neurons were qwantified in the mesencephalon of control (n=4) and chronically MPTP-treated (n=3) baboons. MPTP induced a significant reduction in neuronal cell density in the substantia nigra (63.8% reduction) and the ventral tegmental area (53.1%). Within the substantia nigra, obvious mediolateral and dorsoventral gradients of neuronal cell loss were observed</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Tyrosine 3-monooxygenase</s0>
<s2>FE</s2>
<s5>01</s5>
<s6>Tyrosine «3»-monooxygenase</s6>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Tyrosine 3-monooxygenase</s0>
<s2>FE</s2>
<s5>01</s5>
<s6>Tyrosine «3»-monooxygenase</s6>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Tyrosine 3-monooxygenase</s0>
<s2>FE</s2>
<s5>01</s5>
<s6>Tyrosine «3»-monooxygenase</s6>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Mésencéphale</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Midbrain</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Mesencéfalo</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Neurone dopaminergique</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Dopaminergic neuron</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Neurona dopaminérgica</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s2>NM</s2>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s2>NM</s2>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s2>NM</s2>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Neurotoxine</s0>
<s5>12</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Neurotoxin</s0>
<s5>12</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Neurotoxina</s0>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Pathologie expérimentale</s0>
<s5>13</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Experimental disease</s0>
<s5>13</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Patología experimental</s0>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Animal</s0>
<s5>14</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Animal</s0>
<s5>14</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Animal</s0>
<s5>14</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Singe</s0>
<s5>41</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Monkey</s0>
<s5>41</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Mono</s0>
<s5>41</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>MPTP</s0>
<s4>INC</s4>
<s5>89</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Oxidoreductases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Oxidoreductases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Oxidoreductases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Enzyme</s0>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Enzyme</s0>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Enzima</s0>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Système nerveux central</s0>
<s5>20</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Central nervous system</s0>
<s5>20</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Sistema nervioso central</s0>
<s5>20</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>26</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>26</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>26</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>27</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>27</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>27</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Primates</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Primates</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Primates</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fN21><s1>353</s1>
</fN21>
</pA>
</standard>
<server><NO>PASCAL 94-0715673 INIST</NO>
<ET>Chronic MPTP treatment reproduces in baboons the differential vulnerability of mesencephalic dopaminergic neurons observed in Parkinson's disease</ET>
<AU>VARASTET (M.); RICHE (D.); MAZIERE (M.); HANTRAYE (P.)</AU>
<AF>CEA CNRS, DRIPP, serv. hosp. Frédéric Joliot/91401 Orsay/France (1 aut., 3 aut., 4 aut.); CNRS Inst. Alfred Fessard/91198 Gif-sur-Yvette/France (2 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Neuroscience; ISSN 0306-4522; Coden NRSCDN; Royaume-Uni; Da. 1994; Vol. 63; No. 1; Pp. 47-56; Bibl. 61 ref.</SO>
<LA>Anglais</LA>
<EA>Chronic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to baboons was shown previously to result in a motor syndrome and a pattern of striatal dopaminergic fibre loss similar to those observed in idiopathic Parkinson's disease. In the present study, tyrosine hydroxylase-immunoreactive neurons were qwantified in the mesencephalon of control (n=4) and chronically MPTP-treated (n=3) baboons. MPTP induced a significant reduction in neuronal cell density in the substantia nigra (63.8% reduction) and the ventral tegmental area (53.1%). Within the substantia nigra, obvious mediolateral and dorsoventral gradients of neuronal cell loss were observed</EA>
<CC>002B17G</CC>
<FD>Tyrosine 3-monooxygenase; Mésencéphale; Neurone dopaminergique; Parkinson maladie; Neurotoxine; Pathologie expérimentale; Animal; Singe; MPTP</FD>
<FG>Oxidoreductases; Enzyme; Système nerveux central; Maladie dégénérative; Système nerveux pathologie; Primates; Mammalia; Vertebrata</FG>
<ED>Tyrosine 3-monooxygenase; Midbrain; Dopaminergic neuron; Parkinson disease; Neurotoxin; Experimental disease; Animal; Monkey</ED>
<EG>Oxidoreductases; Enzyme; Central nervous system; Degenerative disease; Nervous system diseases; Primates; Mammalia; Vertebrata</EG>
<SD>Tyrosine 3-monooxygenase; Mesencéfalo; Neurona dopaminérgica; Parkinson enfermedad; Neurotoxina; Patología experimental; Animal; Mono</SD>
<LO>INIST-17194.354000042107130050</LO>
<ID>94-0715673</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001933 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 001933 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:94-0715673
   |texte=   Chronic MPTP treatment reproduces in baboons the differential vulnerability of mesencephalic dopaminergic neurons observed in Parkinson's disease
}}

This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024

	La maladie de Parkinson en France (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson en France (serveur d'exploration)

Chronic MPTP treatment reproduces in baboons the differential vulnerability of mesencephalic dopaminergic neurons observed in Parkinson's disease

Chronic MPTP treatment reproduces in baboons the differential vulnerability of mesencephalic dopaminergic neurons observed in Parkinson's disease

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri